CHOLEBRINE
LOE Approachingiocetamic acid
NDAORALTABLET
Approved
May 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cholebrine (iocetamic acid) is an oral tablet small molecule approved in 1973 for diagnostic imaging of the biliary system. It is a cholecystographic contrast agent that facilitates visualization of gallbladder and bile duct function through iodine-based radiographic contrast properties.
LOE Approaching
Product is in late-stage lifecycle with minimal Part D presence, suggesting a niche diagnostic agent with contracted commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job count reflects the product's mature, niche status with minimal commercial infrastructure. Career growth on Cholebrine is constrained by declining clinical utilization and absence of development pipeline activity.
Product ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.